Scientific Sessions 2024  /  Shifting Paradigms in Chronic Coronary Syndromes: What We Thought We Knew (AHA Joint Session with European Society of Cardiology Society)  /  The Role of Inflammation in Chronic Coronary Disease: New Insights and Therapeutic Targets
Logo

American Heart Association

  2
  0

Final ID:

The Role of Inflammation in Chronic Coronary Disease: New Insights and Therapeutic Targets

  • Libby, Peter  ( BRIGHAM AND WOMENS HOSPITAL , Boston , Massachusetts , United States )
  • Frangogiannis, Nikolaos  ( Albert Einstein , Bronx , New York , United States )
    • Author Disclosures:
    Peter Libby: DO have relevant financial relationships ; Consultant:Amgen, Baim Institute, Beren Therapeutics, Esperion Therapeutics, Genentech, Kancera, Kowa Pharmaceuticals, Novo Nordisk, Novartis, and Sanofi-Regeneron:Active (exists now) ; Other (please indicate in the box next to the company name):Dr. Libby is on the Board of Directors of XBiotech, Inc. Dr. Libby has a financial interest in Xbiotech, a company developing therapeutic human antibodies, in TenSixteen Bio, a company targeting somatic mosaicism and clonal hematopoiesis of indeterminate potential (CHIP) to discover and develop novel therapeutics to treat age-related diseases, and in Soley Therapeutics, a biotechnology company that is combining artificial intelligence with molecular and cellular response detection for discovering and developing new drugs, currently focusing on cancer therapeutics. Dr. Libby’s interests were reviewed and are managed by Brigham and Women’s Hospital and Mass General Brigham in accordance with their conflict-of-interest policies.:Active (exists now) ; Other (please indicate in the box next to the company name):Dr. Libby’s laboratory has received research funding in the last 2 years from Novartis, Novo Nordisk and Genentech:Active (exists now) ; Advisor:AmAmgen, Caristo Diagnostics, CSL Behring, Elucid Bioimaging, Kancera, Kowa Pharmaceuticals, Olatec Therapeutics, Novartis, PlaqueTec, Polygon Therapeutics, TenSixteen Bio, Soley Thereapeutics, and XBiotech, Inc.:Active (exists now) | Nikolaos Frangogiannis: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Shifting Paradigms in Chronic Coronary Syndromes: What We Thought We Knew (AHA Joint Session with European Society of Cardiology Society)

Monday, 11/18/2024 , 08:00AM - 09:15AM

Joint Session

More abstracts on this topic:
Emerging Therapies in Chronic Coronary Syndromes: Beyond Standard Care

Batchelor Wayne, Virani Salim

Angina with non-obstructive coronary arteries (ANOCA/INOCA): Practical management

Berry Colin, Crea Filippo

More abstracts from these authors:
Lipoprotein(a) [Lp(a)]-Enriched Plasma Undergoes More Rapid Oxidation than Small Dense LDL-Enriched Plasma that is Inhibited by Eicosapentaenoic Acid (EPA)

Sherratt Samuel, Libby Peter, Bhatt Deepak, Mason Preston

Novel Lipid Targets and Vascular Outcomes

Libby Peter, Ginsberg Henry

You have to be authorized to contact abstract author. Please, Login
Not Available